SAN FRANCISCO, Nov. 29, 2011 /PRNewswire/ -- Medizone International, Inc. (MZEI:OB MZEI:QB) reports that the Canadian Patent Office has granted Canadian Patent No 2735739 for processes and systems relating to the platform technology of its revolutionary AsepticSure™ hospital disinfection product.
Medizone's lead patent attorney, Robert Hirons, commented on the significance of this Grant: "This foundational lead patent application, 'Healthcare Facility disinfection Process and System with Oxygen/Ozone Mixture' was formally granted as a patent by the Canadian Intellectual Property Office on November 22, 2011. This gives to Medizone the exclusive right to make, use and sell in Canada, the sterilizing apparatus and the sterilizing process covered by the patent, for the full 20-year patent term. In addition, the Canadian patent grant provides a springboard for accelerated issuance of Medizone's corresponding patent applications, e.g. in the United States, with the U.S. Patent Examiners having the benefit of the results of international searches on the novelty of the invention previously generated by the Canadian Examiners."
CEO Edwin Marshall added, "The granting of our foundational patent by the Canadian authorities is confirmation that our patent strategy is sound and on track. It not only signals the beginning of greatly expanded global patent protection for our peer-reviewed AsepticSure™ technology, but brings us another step closer to taking up the fight against superbugs and HAIs, globally. With six international patent applications in place, the foundation for our 'patent protection fence' has now been firmly established."
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation. This Press Release contains certain forward looking statements that may involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com
|SOURCE Medizone International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved